Eris Lifesciences Limited
4,432words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
12%
NTATION INVESTOR PRESENTATION 4th Feb 2025 4th Feb 2025 1 Eris DOMESTIC BRANDED FORMULATIONS -12% ORGANIC GROWTH IN Q3 DOMESTIC BRANDED FORMULATIONS – 12% ORGANIC GROWTH IN Q3 DBF Headline Financ
9%
(INR Cr) YoY Q3 FY25 Q3 FY25 YoY 9M FY25 YoY 9M FY25 YoY Organic Base Organic Base 529* 529* 9% 12% 1,540** 12% 1,540** 9% Ebitda margin Ebitda margin Biocon - 2 Biocon - 2 39% 39% 106 1
39%
529* 529* 9% 12% 1,540** 12% 1,540** 9% Ebitda margin Ebitda margin Biocon - 2 Biocon - 2 39% 39% 106 106 Ebitda margin Ebitda margin 21% 21% 40% 40% 313 313 19% 19% Total DBF Tota
21%
da margin Ebitda margin Biocon - 2 Biocon - 2 39% 39% 106 106 Ebitda margin Ebitda margin 21% 21% 40% 40% 313 313 19% 19% Total DBF Total. DBF 635 635 35% 1,911 1,911 35% 35% 35% D
40%
Ebitda margin Biocon - 2 Biocon - 2 39% 39% 106 106 Ebitda margin Ebitda margin 21% 21% 40% 40% 313 313 19% 19% Total DBF Total. DBF 635 635 35% 1,911 1,911 35% 35% 35% DBF Busines
19%
on - 2 Biocon - 2 39% 39% 106 106 Ebitda margin Ebitda margin 21% 21% 40% 40% 313 313 19% 19% Total DBF Total. DBF 635 635 35% 1,911 1,911 35% 35% 35% DBF Business Highlights DBF Bus
35%
Ebitda margin Ebitda margin 21% 21% 40% 40% 313 313 19% 19% Total DBF Total. DBF 635 635 35% 1,911 1,911 35% 35% 35% DBF Business Highlights DBF Business Highlights • Organic DBF growth bo
237 bps
sion in Base business EBIDTA margin • Expansion in Base business EBIDTA margin • Q3 margin 39% (up 237 bps yoy) • Q3 margin 39% (up 237 bps yoy) • 9M margin 40% (up 266 bps yoy) • 9M margin 40% (up 266 bp
266 bps
DTA margin • Q3 margin 39% (up 237 bps yoy) • Q3 margin 39% (up 237 bps yoy) • 9M margin 40% (up 266 bps yoy) • 9M margin 40% (up 266 bps yoy) • Continued momentum in Business Integration • Continued mo
518 bps
ntinued momentum in Business Integration • Continued momentum in Business Integration • Decline of 518 bps in 9M Gross Margin • Decline of 518 bps in 9M Gross Margin • Largely offset by 460 bps decline in
460 bps
Decline of 518 bps in 9M Gross Margin • Decline of 518 bps in 9M Gross Margin • Largely offset by 460 bps decline in 9M Fixed • Largely offset by 460 bps decline in 9M Fixed Ebitda margin Ebitda margin
36%
decline in 9M Fixed • Largely offset by 460 bps decline in 9M Fixed Ebitda margin Ebitda margin 36% 36% 36% 36% Expenses ratio Expenses ratio Source – Unaudited Financial Statements Source - Una